NCT06754176 Full-Avoidance vs. Permissive/Regulated Drinking & Outcomes On Fibrillation
| NCT ID | NCT06754176 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Atrial Fibrillation (AF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-04-17 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-04-17 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to assess the short-term effects of minimal and moderate drinking on atrial fibrillation (AFib) episodes in a real-world population diagnosed with 'come-and-go'/paroxysmal AFib. The question it aims to answer is: Is there a greater occurrence of AFib episodes when participants are allowed to consume alcohol according to random assignment? Participants will: * Be given daily random assignments to avoid or not to avoid alcohol * Wear an adhesive electrocardiographic (ECG) heart monitor * Wear a wrist-worn fitness tracker * Wear an anklet transdermal alcohol monitor * Wear an adhesive glucose monitor * Complete morning and evening surveys daily Participants may be compensated up to $50 for full completion of the study. This study can be done in-person or remote.
Eligibility Criteria
Inclusion Criteria * Comfortable reading and writing in English * Have a smartphone and willing and able to use the Eureka mobile application * Currently diagnosed with paroxysmal AFib without a plan to change their AFib management during the two-week monitoring period * At least one episode of AFib in the past month OR, in the judgement of a healthcare provider, could potentially have one episode of AF in the next month * Drank alcohol at least 1 day/week on average in the past month * Willing and able to be randomly assigned daily to avoid or not avoid drinking alcohol over a 2-week period * Willing and able to provide written informed consent Exclusion Criteria * Only post-operative AFib * Greater than 40% ventricular pacing * History of alcohol addiction or abuse determined by self-reported history or AUDIT-C score * Intolerance to alcohol * History of liver disease * Currently incarcerated * Currently pregnant or trying to get pregnant
Contact & Investigator
Gregory Marcus, MD, MAS
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT06754176 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Atrial Fibrillation (AF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06754176 currently recruiting?
Yes, NCT06754176 is actively recruiting participants. Contact the research team at greg.marcus@ucsf.edu for enrollment information.
Where is the NCT06754176 trial being conducted?
This trial is being conducted at San Francisco, United States, San Francisco, United States.
Who is sponsoring the NCT06754176 clinical trial?
NCT06754176 is sponsored by University of California, San Francisco. The principal investigator is Gregory Marcus, MD, MAS at University of California, San Francisco. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.